Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
Public ClinicalTrials.gov record NCT00926289. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (Systolic Blood Pressure (SBP) >=160 mmHg and Diastolic Blood Pressure (DBP) >=100 mmHg)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension (SBP\>=160 mmHg and Diastolic Blood Pressure(DBP)\>=100 mmHg).
Study identification
- NCT ID
- NCT00926289
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 894 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Apr 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 27, 2014
Started 2009
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 502.550.01008 Boehringer Ingelheim Investigational Site | Athens | Alabama | — | — |
| 502.550.01019 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 502.550.01015 Boehringer Ingelheim Investigational Site | Lomita | California | — | — |
| 502.550.01003 Boehringer Ingelheim Investigational Site | Colorado Springs | Colorado | — | — |
| 502.550.01014 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 502.550.01002 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 502.550.01011 Boehringer Ingelheim Investigational Site | New Iberia | Louisiana | — | — |
| 502.550.01009 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 502.550.01018 Boehringer Ingelheim Investigational Site | Olive Branch | Mississippi | — | — |
| 502.550.01006 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 502.550.01016 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 502.550.01007 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | — | — |
| 502.550.01005 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 502.550.01001 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 502.550.01017 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 502.550.01020 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 502.550.01012 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 502.550.01004 Boehringer Ingelheim Investigational Site | Arlington | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00926289, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2014 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00926289 live on ClinicalTrials.gov.